YaoGeJu

YaoGeJuCDE public lists · weekly counts

National Drug-Review Weekly

The available CDE acceptance records list 4 drug applications between 17 January 2019 and 23 January 2019 (data as of 13 November 2026 06:00). Of these, generic applications numbered 3, covering 3 drug names.

2019/01/17 – 2019/01/23

Period
2019/01/17 to 2019/01/23, 7 days inclusive
Data as of
2026/11/13 06:00
Cached records
94,806 acceptance records, 11,656 under review now
Source
Public data from the CDE acceptance list and under-review list

The daily national snapshot started on 2026/10/22; the earlier days of this week have no complete acceptance-list snapshot yet, so this week's counts may be lower than the national total.

New acceptances this week
4
Drugs with new generic filings (by drug name, de-duplicated)
3
Accepted this week, now under review
4

DefinitionAcceptance numbers accepted this week that still appear on CDE's under-review list at the data cutoff; counted by acceptance date from the daily full pull of that list, independent of snapshot history.

Names with a public page are linked.

New acceptances this week

By application type and drug type

4filings, 3 of them generic

By application type

Application typeFilings
Generic3
Supplement1

By drug type

Drug typeFilings
Chemical drug4

DefinitionAcceptance numbers whose acceptance date falls in this week; application type and drug type are the CDE list's own text, with empty values shown as “Unspecified”.

Most new generic filings, by drug

3 drugs with new generic filings; top 10 listed

#DrugNew generic filingsFiling companiesUnder review, all years
1吸入用氯化钠溶液 · No verified English name111
2小儿电解质散 · No verified English name111
3氯化钠注射液 · No verified English name1127

DefinitionThis week's acceptance numbers with application type “Generic”, grouped by identical drug name; filing companies are de-duplicated by first applicant; under review, all years = acceptance numbers for that name, from any year, still on the CDE under-review list. Top 10 by filings, then companies.

Most new acceptances, by company

4 companies with new acceptances; top 10 listed

#Company (first applicant)FilingsDrugsGeneric
1Shanghai Zhong Hua Pharma Co., Ltd. romanized110
2Shandong Hua Lu Pharmaceutical Co., Ltd. romanized111
3Shandong Yu Xin Pharma Co., Ltd. romanized111
4Xian An Jian Pharma Co., Ltd. romanized111

DefinitionThis week's acceptance numbers grouped by first applicant; drugs are de-duplicated by drug name; “Generic” counts filings with application type “Generic”. Top 10 by filings.

Under-review list changes

Compared across this platform's snapshots of the under-review list

Data collected since 2026/10/22. There is not enough snapshot history for this week yet; counts of filings entering and leaving review start with the next complete week.

DefinitionEntered review = acceptance numbers seen for the first time in this platform's under-review snapshots this week, excluding the baseline records of the first snapshot day (2026/10/22). Left review = acceptance numbers whose last snapshot sighting falls in this week and that this snapshot no longer lists; the outcome follows NMPA's approval-document delivery notices, and numbers without such a record are marked to be checked. Companies are counted by first applicant.

Class 3 and new-drug acceptances

2 this week

AcceptedDrugApplicants
2019/01/22Generic · Class 3 小儿电解质散 · No verified English nameCYHS1900034 Xian An Jian Pharma Co., Ltd. romanized
2019/01/17Generic · Class 3 吸入用氯化钠溶液 · No verified English nameCYHS1900016 Shandong Hua Lu Pharmaceutical Co., Ltd. romanized

DefinitionThis week's acceptance numbers with application type “New drug”, or registration applications whose class starts with 1, 2 or 3 (supplements and re-registrations excluded); newest first, at most 30 rows.

Subscribe to the weekly

No account needed.

The email carries the same content as this page, in the language you subscribe in: section counts, top-10 lists and definitions, with a link to the full report. Your address is used only to send the report.

A text version of this report, weekly, in the language you subscribe in. You will receive one confirmation email first; sending starts only after you click its link. Every issue carries an unsubscribe link.